Back to CITADEL ADVISORS LLCBBOT
BBOT3 quarters
Position history for CITADEL ADVISORS LLC's holdings in BRIDGEBIO ONCOLOGY THERAPEUT
CITADEL ADVISORS LLC holds 2.5M shares of BBOT (BRIDGEBIO ONCOLOGY THERAPEUT), worth $22.6M as of 2026-Q1. The position was decreased (-0.1% shares). BBOT represents 0.0% of CITADEL ADVISORS LLC's portfolio.
Current Value
$22.6M
Current Shares
2.5M
Total Value Change
-$6.8M
Total Shares Change
-9,379
Quarter-by-Quarter History
Other major holders of BBOT: WELLINGTON MANAGEMENT GROUP LLP, Alphabet Inc., BlackRock, Inc.